Por Renan Filho · 2026-10-30**Lead**
A sweeping new study published this week in the journal *JAMA Network Open* has identified a striking association between a common developmental condition and a substantially increased risk of developing Parkinson's disease and other neurodegenerative movement disorders in adulthood. Researchers analyzing health records from millions of U.S. patients found that individuals diagnosed with the condition were significantly more likely to receive a subsequent diagnosis of Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy compared to the general population. The findings, which have not yet been widely disseminated, are already prompting neurologists to reconsider long-term care protocols for affected individuals.
**Contexto**
The condition in question is attention-deficit/hyperactivity disorder (ADHD), a neurodevelopmental disorder affecting approximately 4.4% of U.S. adults, according to the National Institute of Mental Health. While ADHD has long been associated with executive function challenges, impulsivity, and inattention, its potential connection to later-life neurodegeneration has remained underexplored. The new research, conducted by a team at the University of Utah Health and the George E. Wahlen Veterans Affairs Medical Center, analyzed de-identified electronic health records from nearly 4 million individuals over a 15-year period.
The study cohort included adults aged 50 and older, with a subset having a documented ADHD diagnosis. After adjusting for age, sex, and comorbid conditions such as cardiovascular disease and psychiatric disorders, the researchers observed that those with ADHD had a more than twofold increased risk of developing Parkinson's disease and parkinsonism-related disorders. Notably, the risk was even higher among individuals who had been prescribed stimulant medications for ADHD, although the authors caution that this does not necessarily imply causation—it may reflect greater symptom severity or longer duration of treatment.
This is not the first time a link between ADHD and neurodegeneration has been suggested. Earlier smaller studies, including a 2018 analysis from Taiwan, hinted at a possible association, but the new U.S.-based research provides the most robust evidence to date, leveraging a massive, diverse patient population. The findings align with a growing body of research into the role of dopamine dysregulation in both ADHD and Parkinson's disease. ADHD is characterized by altered dopamine signaling in the brain, and Parkinson's disease is defined by the progressive loss of dopamine-producing neurons in the substantia nigra. This shared neurochemical pathway may explain the observed connection.
**Analise**
The implications of this study are significant for both clinical practice and public health. For the millions of American adults living with ADHD, the findings underscore the importance of vigilant neurological monitoring as they age. Currently, there are no established guidelines for Parkinson's disease screening in ADHD patients, but this research suggests that such protocols may be warranted. Early detection of Parkinson's disease is critical, as interventions can slow disease progression and improve quality of life.
Moreover, the study raises important questions about the long-term effects of stimulant medications, which are the first-line treatment for ADHD. While the increased risk observed among medicated patients could be due to confounding factors, it also highlights the need for further investigation into how chronic dopamine modulation affects brain aging. The authors emphasize that their findings should not discourage appropriate use of ADHD medications, which are highly effective and generally safe, but rather prompt a more nuanced conversation about risk-benefit profiles over a patient's lifespan.
From a research perspective, this study opens new avenues for exploring shared genetic and environmental risk factors between neurodevelopmental and neurodegenerative conditions. If future studies can identify biomarkers that predict which ADHD patients are most vulnerable to Parkinson's disease, it could lead to personalized prevention strategies. Additionally, the findings may inform drug repurposing efforts—for instance, testing whether certain ADHD medications have neuroprotective properties or, conversely, whether they accelerate neurodegeneration in susceptible individuals.
The study also has broader implications for how we conceptualize mental health and neurological disorders. Historically, ADHD has been viewed as a childhood condition that resolves with age, but this research reinforces the notion that it is a lifelong condition with far-reaching consequences. As the U.S. population ages, understanding these connections will become increasingly important for healthcare systems, which must prepare for a potential rise in Parkinson's disease cases among older adults with a history of ADHD.
**Fontes**
The information in this article is based on the peer-reviewed study published in *JAMA Network Open* (October 2025), conducted by researchers at University of Utah Health and the George E. Wahlen Veterans Affairs Medical Center. Additional context was drawn from the National Institute of Mental Health's statistics on adult ADHD prevalence and prior research published in the journal *Neurology* (2018) regarding ADHD and Parkinson's risk in Asian populations. No direct interviews were conducted for this report.